Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
National Cancer Institute, Naples
The standard first-line treatment of ovarian cancer is combination chemotherapy with carboplatin and paclitaxel, given every 3 weeks. Researchers are looking at new ways of giving chemotherapy to make it more tolerable and more effective. One way is by giving the chemotherapy more often in smaller doses. This approach can be associated with fewer or less troubling side effects. Some chemotherapy drugs such as paclitaxel have been shown to also be more active when given once a week rather than once every 3 week schedule.
Age
18–any
Sex
FEMALE
Healthy volunteers
Not accepted
You may be eligible if
Cytologic or histologic diagnosis of ovarian carcinoma of the ovary, fallopian tube or primary peritoneal carcinoma, stage IC-IV
Indication for chemotherapy
Age \> 18 years
Life expectancy of at least 3 months
You may not be if
Previous or concomitant malignant malignancy (excluding adequately treated baso-or squamocellular carcinoma of the skin and carcinoma in situ of the cervix, and synchronous endometrioid carcinoma Stage Ib or less for the uterus, with ovarian tumor Stage II or higher)
Performance Status (ECOG) \> or = 3.
Previous chemotherapy
Heart disease (congestive heart failure, myocardial infarction within 6 months from study entry, atrioventricular block of any grade, severe arrhythmias)
Neutrophils \< 2000 x mm3, platelets \< 100000 x mm3
Inadequate renal function (creatinine \> or = 1.25 x normal values) or liver function (ALT or AST \> or = 1.25 x normal values)
Present or suspected hemorrhagic syndromes
Inability to comply with protocol and follow-up
Inability to access study site for clinical visits
Refusal of informed consent
Clareo Health | Study Comparing Weekly Versus Every 3 Week Chemotherapy in Patients With Ovarian Cancer